Cecelia H. Boardman

Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study

Bradley J. Monk, Michael W. Sill, D. Scott McMeekin et al. · Journal of Clinical Oncology · 2009 · 681 citations · Full text

Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group

David S. Miller, John A. Blessing, Carolyn Krasner et al. · Journal of Clinical Oncology · 2009 · 182 citations · Full text

Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study

Alessandro D. Santin, Michael W. Sill, D. Scott McMeekin et al. · Gynecologic Oncology · 2011 · 108 citations

Cervical Cancer Management, Cervical Cancer, Phase Ii Trial +9

Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.

Andre T. Baron, Elsa M. Cora, Jacqueline M. Lafky et al. · PubMed · 2003 · 97 citations

Diagnostic Serum Biomarker, Eoc Patients, Oncology +14

Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.

Andre T. Baron, Jacqueline M. Lafky, Cecelia H. Boardman et al. · PubMed · 1999 · 68 citations

Epithelial Ovarian Cancer, Gynecology, Pathology +16